ASX:SPL - Starpharma Stock Price, News & Analysis

+0.04 (+3.31 %)
(As of 08/20/2019 07:41 AM ET)
Today's Range
Now: A$1.25
50-Day Range
MA: A$1.31
52-Week Range
Now: A$1.25
Volume105,781 shs
Average Volume544,824 shs
Market Capitalization$464.62 million
P/E RatioN/A
Dividend YieldN/A
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$4.37 million
Cash FlowA$0.12 per share
Book ValueA$0.13 per share



Market Cap$464.62 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SPL News and Ratings via Email

Sign-up to receive the latest news and ratings for SPL and its competitors with MarketBeat's FREE daily newsletter.

Starpharma (ASX:SPL) Frequently Asked Questions

What is Starpharma's stock symbol?

Starpharma trades on the ASX under the ticker symbol "SPL."

Has Starpharma been receiving favorable news coverage?

News coverage about SPL stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Starpharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Starpharma.

Who are some of Starpharma's key competitors?

What other stocks do shareholders of Starpharma own?

Who are Starpharma's key executives?

Starpharma's management team includes the folowing people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 56)
  • Mr. Nigel J. Baade, CFO & Company Sec.
  • Dr. A. Eglezos BSc(Hons), Ph.D., MBA, VP of Bus. Devel.
  • Dr. Jeremy R. Paull BSc (Hons), Ph.D., VP of Devel. & Regulatory Affairs
  • Dr. David J. Owen BSc(Hons) Ph.D., VP of Research

What is Starpharma's stock price today?

One share of SPL stock can currently be purchased for approximately A$1.25.

How big of a company is Starpharma?

Starpharma has a market capitalization of $464.62 million and generates $4.37 million in revenue each year. View Additional Information About Starpharma.

What is Starpharma's official website?

The official website for Starpharma is

How can I contact Starpharma?

Starpharma's mailing address is 4-6 Southampton Cres, MELBOURNE, VIC 3067, Australia. The company can be reached via phone at +61-3-85322700.

MarketBeat Community Rating for Starpharma (ASX SPL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  56 (Thanks for Voting!)
Underperform Votes:  62 (Thanks for Voting!)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Starpharma and other stocks. Vote "Outperform" if you believe SPL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel